Stephen B Liggett

List of Publications by Year
in descending order

186	15,155	17405 63	19136 118
papers	citations	h-index	g-index

190	190	190	10829
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Î²-arrestin1 promotes tauopathy by transducing GPCR signaling, disrupting microtubules and autophagy. Life Science Alliance, 2022, 5, e202101183.	1.3	9
2	Biased Î²-Agonists Favoring Gs over Î²-Arrestin for Individualized Treatment of Obstructive Lung Disease. Journal of Personalized Medicine, 2022, 12, 331.	1.1	6
3	Î±_{1B/D}-adrenoceptors regulate chemokine receptorâ€“mediated leukocyte migration via formation of heteromeric receptor complexes. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2123511119.	3.3	5
4	Selective Signal Capture from Multidimensional GPCR Outputs with Biased Agonists: Progress Towards Novel Drug Development. Molecular Diagnosis and Therapy, 2022, 26, 383-396.	1.6	2
5	Structures and Agonist Binding Sites of Bitter Taste Receptor TAS2R5 Complexed with Gi Protein and Validated against Experiment. Journal of Physical Chemistry Letters, 2021, 12, 9293-9300.	2.1	5
6	The short third intracellular loop and cytoplasmic tail of bitter taste receptors provide functionally relevant GRK phosphorylation sites in TAS2R14. Journal of Biological Chemistry, 2021, 296, 100216.	1.6	2
7	Identification and characterization of an atypical GÎ±s-biased Î² ₂ AR agonist that fails to evoke airway smooth muscle cell tachyphylaxis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	12
8	Rhinovirus C15 Induces Airway Hyperresponsiveness via Calcium Mobilization in Airway Smooth Muscle. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 310-318.	1.4	14
9	Identification and Characterization of Novel Bronchodilator Agonists Acting at Human Airway Smooth Muscle Cell TAS2R5. ACS Pharmacology and Translational Science, 2020, 3, 1069-1075.	2.5	5
10	The odorant receptor OR2W3 on airway smooth muscle evokes bronchodilation via a cooperative chemosensory tradeoff between TMEM16A and CFTR. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28485-28495.	3.3	11
11	Î²-Arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5006-5015.	3.3	34
12	Differential longâ€term regulation of TAS2R14 by structurally distinct agonists. FASEB Journal, 2019, 33, 12213-12225.	0.2	10
13	Development of a Rhinovirus Inoculum Using a Reverse Genetics Approach. Journal of Infectious Diseases, 2019, 220, 187-194.	1.9	6
14	A microphysiological model of the bronchial airways reveals the interplay of mechanical and biochemical signals in bronchospasm. Nature Biomedical Engineering, 2019, 3, 532-544.	11.6	25
15	Activated cofilin exacerbates tau pathology by impairing tau-mediated microtubule dynamics. Communications Biology, 2019, 2, 112.	2.0	39
16	Biased TAS2R Bronchodilators Inhibit Airway Smooth Muscle Growth by Downregulating Phosphorylated Extracellular Signalâ€“regulated Kinase 1/2. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 532-540.	1.4	24
17	Pepducins as a potential treatment strategy for asthma and COPD. Current Opinion in Pharmacology, 2018, 40, 120-125.	1.7	13
18	Genetic Vulnerability of GPCRs: A Call to Action. Trends in Biochemical Sciences, 2018, 43, 227-229.	3.7	3

#	Article	IF	Citations
19	Taste and smell GPCRs in the lung: Evidence for a previously unrecognized widespread chemosensory system. Cellular Signalling, 2018, 41, 82-88.	1.7	67
20	Preface to Special Issue on â€˜Cytochrome P450 Variation in Pharmacogenomicsâ€™. Journal of Personalized Medicine, 2018, 8, 23.	1.1	0
21	Dose Response of Î²-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circulation Genomic and Precision Medicine, 2018, 11, e002210.	1.6	8
22	A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in African Americans. Journal of Personalized Medicine, 2018, 8, 11.	1.1	38
23	A CREBâ€mediated increase in miRNAletâ€7fduring prolonged Î²â€agonist exposure: a novel mechanism of Î²₂â€adrenergic receptor downâ€regulation in airway smooth muscle. FASEB Journal, 2018, 32, 3680-3688.	0.2	13
24	Coupling of Airway Smooth Muscle Bitter Taste Receptors to Intracellular Signaling and Relaxation Is via G_{Î±i1,2,3}. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 762-771.	1.4	54
25	Defining an olfactory receptor function in airway smooth muscle cells. Scientific Reports, 2016, 6, 38231.	1.6	83
26	Inhibition of PI3K promotes dilation of human small airways in a rho kinaseâ€dependent manner. British Journal of Pharmacology, 2016, 173, 2726-2738.	2.7	34
27	Î²2-Adrenergic Receptors Chaperone Trapped Bitter Taste Receptor 14 to the Cell Surface as a Heterodimer and Exert Unidirectional Desensitization of Taste Receptor Function. Journal of Biological Chemistry, 2016, 291, 17616-17628.	1.6	24
28	An inflammation-independent contraction mechanophenotype of airway smooth muscle in asthma. Journal of Allergy and Clinical Immunology, 2016, 138, 294-297.e4.	1.5	52
29	Future Translational Applications From the Contemporary Genomics Era. Circulation, 2015, 131, 1715-1736.	1.6	38
30	Polymorphisms in human heat shock factor-1 and analysis of potential biological consequences. Cell Stress and Chaperones, 2015, 20, 47-59.	1.2	4
31	Pleiotropic Effects of Bitter Taste Receptors on [Ca2+]i Mobilization, Hyperpolarization, and Relaxation of Human Airway Smooth Muscle Cells. PLoS ONE, 2015, 10, e0131582.	1.1	40
32	Targeted transgenesis identifies GÎ±s as the bottleneck in Î²2-adrenergic receptor cell signaling and physiological function in airway smooth muscle. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 307, L775-L780.	1.3	6
33	Genome Sequences of Rhinovirus A Isolates from Wisconsin Pediatric Respiratory Studies. Genome Announcements, 2014, 2, .	0.8	3
34	Genome Sequences of Rhinovirus C Isolates from Wisconsin Pediatric Respiratory Studies. Genome Announcements, 2014, 2, .	0.8	4
35	Race, Common Genetic Variation, and Therapeutic Response Disparities in Heart Failure. JACC: Heart Failure, 2014, 2, 561-572.	1.9	33
36	Bitter Taste Receptor Function in Asthmatic and Nonasthmatic Human Airway Smooth Muscle Cells. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 678-683.	1.4	71

#	Article	IF	Citations
37	Genome Sequences of Rhinovirus B Isolates from Wisconsin Pediatric Respiratory Studies. Genome Announcements, 2014, 2, .	0.8	1
38	Regulation of Intracellular Calcium by Bitter Taste Receptors on Airway Smooth Muscle. , 2014, , 409-421.		0
39	Bitter taste receptors in the wrong place: novel airway smooth muscle targets for treating asthma. Transactions of the American Clinical and Climatological Association, 2014, 125, 64-74; discussion 74-5.	0.9	16
40	Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta 1 389 Arg/Gly Adrenergic Receptor Polymorphism. JACC: Heart Failure, 2013, 1, 338-344.	1.9	43
41	Bitter taste receptors on airway smooth muscle as targets for novel bronchodilators. Expert Opinion on Therapeutic Targets, 2013, 17, 721-731.	1.5	38
42	Adrenergic Receptor Polymorphisms and Prevention of Ventricular Arrhythmias With Bucindolol in Patients With Chronic Heart Failure. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 137-143.	2.1	31
43	TAS2R activation promotes airway smooth muscle relaxation despite Î²₂-adrenergic receptor tachyphylaxis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 303, L304-L311.	1.3	76
44	G protein receptor kinase 4 polymorphisms. Hypertension, 2012, 60, 957-964.	1.3	65
45	Reply to: Activation of BK channels may not be required for bitter tastantâ€“induced bronchodilation. Nature Medicine, 2012, 18, 650-651.	15.2	29
46	Extraoral bitter taste receptors as mediators of offâ€target drug effects. FASEB Journal, 2012, 26, 4827-4831.	0.2	123
47	Adrenergic Receptor Polymorphisms in Heart Failure. , 2012, , 661-672.		0
48	Combinatorial Pharmacogenetic Interactions of Bucindolol and Î²1, Î±2C Adrenergic Receptor Polymorphisms. PLoS ONE, 2012, 7, e44324.	1.1	55
49	Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. Nature Medicine, 2011, 17, 627-632.	15.2	177
50	Temporal analysis of mRNA and miRNA expression in transgenic mice overexpressing Arg- and Gly389 polymorphic variants of the Î²₁-adrenergic receptor. Physiological Genomics, 2011, 43, 1294-1306.	1.0	17
51	Hypertrophyâ€Associated Polymorphisms Ascertained in a Founder Cohort Applied to Heart Failure Risk and Mortality. Clinical and Translational Science, 2011, 4, 17-23.	1.5	35
52	Regulatory Haplotypes inARG1Are Associated with Altered Bronchodilator Response. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 449-454.	2.5	56
53	Agonist-Promoted Homologous Desensitization of Human Airway Smooth Muscle Bitter Taste Receptors. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 1069-1074.	1.4	49
54	Phosphorylation Barcoding as a Mechanism of Directing GPCR Signaling. Science Signaling, 2011, 4, pe36.	1.6	118

#	Article	IF	Citations
55	MicroRNA let-7 establishes expression of Î² ₂ -adrenergic receptors and dynamically down-regulates agonist-promoted down-regulation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6246-6251.	3.3	41
56	Bronchodilator activity of bitter tastants in human tissue. Nature Medicine, 2011, 17, 776-778.	15.2	40
57	Paradoxical attenuation of Î²₂-AR function in airway smooth muscle by G_i-mediated counterregulation in transgenic mice overexpressing type 5 adenylyl cyclase. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L472-L478.	1.3	10
58	Genetic Variation, Î²-blockers, and Perioperative Myocardial Infarction. Anesthesiology, 2011, 115, 1316-1327.	1.3	32
59	Î²2-Agonist Induced cAMP Is Decreased in Asthmatic Airway Smooth Muscle Due to Increased PDE4D. PLoS ONE, 2011, 6, e20000.	1.1	81
60	Polymorphisms of heat shock factorâ€1: Genetic diversity in an evolutionarily conserved, multifunctional regulator gene. FASEB Journal, 2011, 25, lb35.	0.2	0
61	Full-genome sequence and analysis of a novel human rhinovirus strain within a divergent HRV-A clade. Archives of Virology, 2010, 155, 83-87.	0.9	16
62	Striated muscle tropomyosin isoforms differentially regulate cardiac performance and myofilament calcium sensitivity. Journal of Muscle Research and Cell Motility, 2010, 31, 227-239.	0.9	25
63	Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction. Nature Medicine, 2010, 16, 1299-1304.	15.2	549
64	Common ADRB2 Haplotypes Derived from 26 Polymorphic Sites Direct Î²2-Adrenergic Receptor Expression and Regulation Phenotypes. PLoS ONE, 2010, 5, e11819.	1.1	40
65	Molecular and Functional Characterization of a Novel Cardiac-Specific Human Tropomyosin Isoform. Circulation, 2010, 121, 410-418.	1.6	89
66	An Î± 2C -Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the Î²-Blocker Bucindolol in Chronic Heart Failure. Circulation: Heart Failure, 2010, 3, 21-28.	1.6	103
67	Pharmacogenomics of Î²1-Adrenergic Receptor Polymorphisms in Heart Failure. Heart Failure Clinics, 2010, 6, 27-33.	1.0	23
68	Analysis of the complete genome sequences of human rhinovirus. Journal of Allergy and Clinical Immunology, 2010, 125, 1190-1199.	1.5	93
69	Sequencing and Analyses of All Known Human Rhinovirus Genomes Reveal Structure and Evolution. Science, 2009, 324, 55-59.	6.0	416
70	Targeted transgenesis reveals discrete attenuator functions of GRK and PKA in airway Î² ₂ -adrenergic receptor physiologic signaling. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15007-15012.	3.3	32
71	Î± _{2A} -Adrenergic Receptors in the Genetics, Pathogenesis, and Treatment of Type 2 Diabetes. Science Translational Medicine, 2009, 1, 12ps15.	5.8	23
72	An internal domain of Î²-tropomyosin increases myofilament Ca²⁺sensitivity. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H181-H190.	1.5	11

#	Article	IF	Citations
73	Mechanisms of Pharmacogenomic Effects of Genetic Variation within the Cardiac Adrenergic Network in Heart Failure. Molecular Pharmacology, 2009, 76, 466-480.	1.0	51
74	Multiple interactions between the alpha2C- and beta1-adrenergic receptors influence heart failure survival. BMC Medical Genetics, 2008, 9, 93.	2.1	16
75	A GRK5 polymorphism that inhibits Î²-adrenergic receptor signaling is protective in heart failure. Nature Medicine, 2008, 14, 510-517.	15.2	297
76	Pharmacogenomics of Î²â€Adrenergic Receptors and Their Accessory Signaling Proteins in Heart Failure. Clinical and Translational Science, 2008, 1, 255-262.	1.5	17
77	Bitransgenesis with Î²₂â€Adrenergic Receptors or Adenylyl Cyclase Fails to Improve Î²₁â€Adrenergic Receptor Cardiomyopathy. Clinical and Translational Science, 2008, 1, 221-227.	1.5	7
78	Lack of Association Between Adrenergic Receptor Genotypes and Survival in Heart Failure Patients Treated With Carvedilol or Metoprolol. Journal of the American College of Cardiology, 2008, 52, 644-651.	1.2	124
79	Genetic Variation Within the Î²1-Adrenergic Receptor Gene Results in Haplotype-Specific Expression Phenotypes. Journal of Cardiovascular Pharmacology, 2008, 51, 106-110.	0.8	17
80	Alternative splicing of the G protein-coupled receptor superfamily in human airway smooth muscle diversifies the complement of receptors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5230-5235.	3.3	70
81	Differential coupling of Arg- and Gly389 polymorphic forms of the Î²1-adrenergic receptor leads to pathogenic cardiac gene regulatory programs. Physiological Genomics, 2008, 35, 123-131.	1.0	11
82	A polymorphism of G-protein coupled receptor kinase5 alters agonist-promoted desensitization of Î²2-adrenergic receptors. Pharmacogenetics and Genomics, 2008, 18, 729-732.	0.7	46
83	Variable-length poly-C tract polymorphisms of the Î²2-adrenergic receptor 3â€²-UTR alter expression and agonist regulation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L190-L195.	1.3	20
84	ARG1 Is a Novel Bronchodilator Response Gene. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 688-694.	2.5	121
85	Heterogeneity of transcription factor expression and regulation in human airway epithelial and smooth muscle cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 293, L453-L462.	1.3	11
86	Rescue of tropomyosin-induced familial hypertrophic cardiomyopathy mice by transgenesis. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H949-H958.	1.5	47
87	Pleiotropic Î²-Agonistâ€“Promoted Receptor Conformations and Signals Independent of Intrinsic Activity. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 236-243.	1.4	16
88	Allele-Specific Binding of Airway Nuclear Extracts to Polymorphic Î²2-Adrenergic Receptor 5â€² Sequence. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 654-660.	1.4	13
89	Tight control of adrenal medulla catecholamine release by Î±2C-adrenergic receptors influences susceptibility to heart failure. Cardiovascular Research, 2007, 75, 631-633.	1.8	0
90	A functional polymorphism of the GÂq (GNAQ) gene is associated with accelerated mortality in African-American heart failure. Human Molecular Genetics, 2007, 16, 2740-2750.	1.4	21

#	Article	IF	Citations
91	Dilated Cardiomyopathy Mutant Tropomyosin Mice Develop Cardiac Dysfunction With Significantly Decreased Fractional Shortening and Myofilament Calcium Sensitivity. Circulation Research, 2007, 101, 205-214.	2.0	86
92	Long-distance affair with adrenal GRK2 hangs up heart failure. Nature Medicine, 2007, 13, 246-248.	15.2	5
93	Crosstalk between Gi and Gq/Gs pathways in airway smooth muscle regulates bronchial contractility and relaxation. Journal of Clinical Investigation, 2007, 117, 1391-1398.	3.9	58
94	Î±2A- and Î±2C-Adrenergic Receptors Form Homo- and Heterodimers:â€‰ The Heterodimeric State Impairs Agonist-Promoted GRK Phosphorylation and Î²-Arrestin Recruitment. Biochemistry, 2006, 45, 4760-4767.	1.2	64
95	Transcriptional response to persistent Î²2-adrenergic receptor signaling reveals regulation of phospholamban, which alters airway contractility. Physiological Genomics, 2006, 27, 171-177.	1.0	20
96	Sequence, Haplotype, and Association Analysis ofADRÎ²2in a Multiethnic Asthma Case-Control Study. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1101-1109.	2.5	167
97	Complex haplotypes derived from noncoding polymorphisms of the intronless Â2A-adrenergic gene diversify receptor expression. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5472-5477.	3.3	43
98	Myocardial Î²1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H1427-H1432.	1.5	34
99	The Presence of Lys27 Instead of Asn27 in Human Phospholamban Promotes Sarcoplasmic Reticulum Ca 2+ -ATPase Superinhibition and Cardiac Remodeling. Circulation, 2006, 113, 995-1004.	1.6	37
100	Î² 2 -Adrenergic Receptor Polymorphisms and Sudden Cardiac Death. Circulation, 2006, 113, 1818-1820.	1.6	19
101	A polymorphism within a conserved beta1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11288-11293.	3.3	435
102	Airway smooth muscle prostaglandin-EP1 receptors directly modulate Â2-adrenergic receptors within a unique heterodimeric complex. Journal of Clinical Investigation, 2006, 116, 1400-1409.	3.9	113
103	Cardiac 7-transmembrane-spanning domain receptor portfolios: diversify, diversify, diversify. Journal of Clinical Investigation, 2006, 116, 875-877.	3.9	9
104	Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between Î²-agonist and corticosteroid pathways. Human Molecular Genetics, 2005, 14, 1671-1677.	1.4	121
105	Lymphocyte GRK levels as biomarkers in heart failureThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2005, 26, 1695-1696.	1.0	2
106	Molecular Mechanisms of Â2-Adrenergic Receptor Function and Regulation. Proceedings of the American Thoracic Society, 2005, 2, 292-296.	3.5	70
107	Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Human Molecular Genetics, 2004, 13, 1353-1359.	1.4	315
108	Polymorphisms of cardiac presynaptic Â2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13020-13025.	3.3	51

#	Article	IF	Citations
109	A Primate-dominant Third Glycosylation Site of the Î²2-Adrenergic Receptor Routes Receptors to Degradation during Agonist Regulation. Journal of Biological Chemistry, 2004, 279, 38603-38607.	1.6	42
110	The two-timing thyroid. Nature Medicine, 2004, 10, 582-583.	15.2	19
111	PKC-Î± regulates cardiac contractility and propensity toward heart failure. Nature Medicine, 2004, 10, 248-254.	15.2	551
112	Genetically modified mouse models for pharmacogenomic research. Nature Reviews Genetics, 2004, 5, 657-663.	7.7	30
113	Medetomidine analogs as selective agonists for the human Î±2-adrenoceptors. Biochemical Pharmacology, 2004, 67, 87-96.	2.0	16
114	Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet, The, 2004, 364, 1505-1512.	6.3	592
115	Î²-Adrenergic Receptors. , 2004, , 57-59.		0
116	Hereditary dysautonomias: current knowledge and collaborations for the future. Clinical Autonomic Research, 2003, 13, 180-195.	1.4	2
117	Activity of the uptake-1 norepinephrine transporter as measured by I-123 MIBG in heart failure patients with a loss-of-function polymorphism of the presynaptic Î±2Câ€“adrenergic receptor. Journal of Nuclear Cardiology, 2003, 10, 583-589.	1.4	20
118	Î²1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nature Medicine, 2003, 9, 1300-1305.	15.2	328
119	PHARMACOLOGY ANDPHYSIOLOGY OFHUMANADRENERGICRECEPTORPOLYMORPHISMS. Annual Review of Pharmacology and Toxicology, 2003, 43, 381-411.	4.2	301
120	Gene and Protein Domain-Specific Patterns of Genetic Variability Within the G-Protein Coupled Receptor Superfamily. Molecular Diagnosis and Therapy, 2003, 3, 65-71.	3.3	24
121	Protein Kinase CÎ± Negatively Regulates Systolic and Diastolic Function in Pathological Hypertrophy. Circulation Research, 2003, 93, 1111-1119.	2.0	114
122	Hierarchy of Polymorphic Variation and Desensitization Permutations Relative to Î²1- and Î²2-Adrenergic Receptor Signaling. Journal of Biological Chemistry, 2003, 278, 10784-10789.	1.6	65
123	Polymorphisms of Adrenergic Receptors: Variations on a Theme. Assay and Drug Development Technologies, 2003, 1, 317-326.	0.6	22
124	Common Genomic Response in Different Mouse Models of Î²-Adrenergicâ€“Induced Cardiomyopathy. Circulation, 2003, 108, 2926-2933.	1.6	68
125	An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced ??2-adrenergic receptor stimulation. Pharmacogenetics and Genomics, 2003, 13, 535-541.	5.7	55
126	Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. Journal of Clinical Investigation, 2003, 111, 869-876.	3.9	380

#	Article	IF	Citations
127	Antithetic regulation by Î²-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway Î²-agonist paradox. Journal of Clinical Investigation, 2003, 112, 619-626.	3.9	112
128	Synergistic Polymorphisms of Î²1- and Î±2C-Adrenergic Receptors and the Risk of Congestive Heart Failure. New England Journal of Medicine, 2002, 347, 1135-1142.	13.9	529
129	Amino Acid 49 Polymorphisms of the Human Î² 1 -Adrenergic Receptor Affect Agonist-Promoted Trafficking. Journal of Cardiovascular Pharmacology, 2002, 39, 155-160.	0.8	194
130	Polymorphisms of the Î²1-adrenergic receptor predict exercise capacity in heart failure. American Heart Journal, 2002, 144, 840-846.	1.2	124
131	Polymorphisms of the Î²2-Adrenergic Receptor. New England Journal of Medicine, 2002, 346, 536-538.	13.9	47
132	Yohimbine Dimers Exhibiting Selectivity for the Human Î±2c-Adrenoceptor Subtype. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 979-984.	1.3	30
133	Identification of adrenergic receptor polymorphisms. Methods in Enzymology, 2002, 343, 459-475.	0.4	38
134	Update on current concepts of the molecular basis of Î²2-adrenergic receptor signaling. Journal of Allergy and Clinical Immunology, 2002, 110, S223-S228.	1.5	75
135	False positive non-synonymous polymorphisms of G-protein coupled receptor genes. FEBS Letters, 2002, 516, 253-256.	1.3	19
136	Phosphorylation of Ser360 in the third intracellular loop of the Î±2A-adrenoceptor during protein kinase C-mediated desensitization. European Journal of Pharmacology, 2002, 437, 41-46.	1.7	12
137	Identification and functional characterization of Î±2-adrenoceptor polymorphisms. Trends in Pharmacological Sciences, 2001, 22, 471-477.	4.0	59
138	Serine 232 of the Î±2A-Adrenergic Receptor Is a Protein Kinase C-Sensitive Effector Coupling Switchâ€. Biochemistry, 2001, 40, 15031-15037.	1.2	7
139	Targeted transgenic expression of Î²₂-adrenergic receptors to type II cells increases alveolar fluid clearance. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L895-L903.	1.3	41
140	Pharmacogenetic applications of the Human Genome project. Nature Medicine, 2001, 7, 281-283.	15.2	87
141	The Ile164 Î²2-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to Gs. European Journal of Pharmacology, 2001, 421, 141-147.	1.7	87
142	Polymorphic Deletion of Three Intracellular Acidic Residues of the Î±2B-Adrenergic Receptor Decreases G Protein-coupled Receptor Kinase-mediated Phosphorylation and Desensitization. Journal of Biological Chemistry, 2001, 276, 4917-4922.	1.6	137
143	Effect of Polymorphism of the Î²₂-Adrenergic Receptor on Response to Regular Use of Albuterol in Asthma. International Archives of Allergy and Immunology, 2001, 124, 183-186.	0.9	102
144	Modification of the Î²2-Adrenergic Receptor to Engineer a Receptor-Effector Complex for Gene Therapy. Journal of Biological Chemistry, 2001, 276, 31596-31601.	1.6	34

#	Article	IF	Citations
145	Interactions Between Phospholamban and Î²-Adrenergic Drive May Lead to Cardiomyopathy and Early Mortality. Circulation, 2001, 103, 889-896.	1.6	100
146	Î²-Adrenergic receptors in the failing heart: the good, the bad, and the unknown. Journal of Clinical Investigation, 2001, 107, 947-948.	3.9	39
147	Transgenic overexpression of Î²₂-adrenergic receptors in airway epithelial cells decreases bronchoconstriction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L379-L389.	1.3	31
148	An Asn to Lys Polymorphism in the Third Intracellular Loop of the Human Î±2A-Adrenergic Receptor Imparts Enhanced Agonist-promoted Gi Coupling. Journal of Biological Chemistry, 2000, 275, 38518-38523.	1.6	67
149	A Four Amino Acid Deletion Polymorphism in the Third Intracellular Loop of the Human Î±2C-Adrenergic Receptor Confers Impaired Coupling to Multiple Effectors. Journal of Biological Chemistry, 2000, 275, 23059-23064.	1.6	171
150	Î±2A/Î±2C-Adrenergic Receptor Third Loop Chimera Show That Agonist Interaction with Receptor Subtype Backbone Establishes G Protein-coupled Receptor Kinase Phosphorylation. Journal of Biological Chemistry, 2000, 275, 28989-28993.	1.6	24
151	Pharmacogenetics of Beta-1- and Beta-2-Adrenergic Receptors. Pharmacology, 2000, 61, 167-173.	0.9	133
152	Polymorphisms of the Î² ₂ -Adrenergic Receptor Determine Exercise Capacity in Patients With Heart Failure. Circulation Research, 2000, 86, 834-840.	2.0	171
153	Î²2-Adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. American Heart Journal, 2000, 139, 537-542.	1.2	121
154	The pharmacogenetics of Î²2-adrenergic receptors: Relevance to asthma. Journal of Allergy and Clinical Immunology, 2000, 105, S487-S492.	1.5	82
155	Functional Receptor Coupling to Gils A Mechanism of Agonist-Promoted Desensitization of the Î²2-Adrenergic Receptor. Journal of Receptor and Signal Transduction Research, 2000, 20, 75-85.	1.3	22
156	Fusion of Î²2-Adrenergic Receptor to GÎ±s in Mammalian Cells:â€‰ Identification of a Specific Signal Transduction Species Not Characteristic of Constitutive Activation or Precoupling. Biochemistry, 2000, 39, 2815-2821.	1.2	20
157	Histamine N-methyltransferase pharmacogenetics: association of a common functional polymorphism with asthma. Pharmacogenetics and Genomics, 2000, 10, 261-266.	5.7	89
158	[beta]-Adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. American Heart Journal, 2000, 139, 0537-0542.	1.2	4
159	Transgenic Overexpression of Î²2-Adrenergic Receptors in Airway Smooth Muscle Alters Myocyte Function and Ablates Bronchial Hyperreactivity. Journal of Biological Chemistry, 1999, 274, 32241-32247.	1.6	57
160	Plastic Adenylyl Cyclase. American Journal of Respiratory Cell and Molecular Biology, 1999, 21, 564-566.	1.4	4
161	Cardiac Specific Overexpression of Transglutaminase II (Gh) Results in a Unique Hypertrophy Phenotype Independent of Phospholipase C Activation. Journal of Biological Chemistry, 1999, 274, 21291-21296.	1.6	94
162	A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human Î²1-Adrenergic Receptor. Journal of Biological Chemistry, 1999, 274, 12670-12674.	1.6	540

#	Article	IF	Citations
163	Racial differences in the frequencies of cardiac ?1-adrenergic receptor polymorphisms: Analysis of c145A>G and c1165G>C. , 1999, 14, 271-271.		93
164	Transgenic replacement of type V adenylyl cyclase identifies a critical mechanism of Î²-adrenergic receptor dysfunction in the GÎ±qoverexpressing mouse. FEBS Letters, 1999, 458, 236-240.	1.3	53
165	Molecular and genetic basis of Î²2 -adrenergic receptor functionâ˜†â˜†â˜†. Journal of Allergy and Clinical Immunology, 1999, 104, S42-S46.	1.5	57
166	Altering the Receptorâ"Effector Ratio by Transgenic Overexpression of Type V Adenylyl Cyclase:Â Enhanced Basal Catalytic Activity and Function without Increased Cardiomyocyte Î²-Adrenergic Signallingâ€. Biochemistry, 1999, 38, 16706-16713.	1.2	61
167	Role of Î²ARK in Long-Term Agonist-Promoted Desensitisation of the Î²2-Adrenergic Receptor. Cellular Signalling, 1998, 10, 197-204.	1.7	22
168	Agonist-Mediated Downregulation of GÎ±ivia the Î±2-Adrenergic Receptor Is Targeted by Receptor-GiInteraction and Is Independent of Receptor Signaling and Regulationâ€. Biochemistry, 1998, 37, 15720-15725.	1.2	29
169	Decompensation of Pressure-Overload Hypertrophy in GÎ±q-Overexpressing Mice. Circulation, 1998, 97, 1488-1495.	1.6	199
170	Phosphorylation and Functional Desensitization of the Î±_{2A}-Adrenergic Receptor by Protein Kinase C. Molecular Pharmacology, 1998, 54, 44-49.	1.0	41
171	Heterogeneity in Î²-Adrenergic Receptor Kinase Expression in the Lung Accounts for Cell-specific Desensitization of the Î²2-Adrenergic Receptor. Journal of Biological Chemistry, 1997, 272, 7338-7344.	1.6	79
172	Structural Determinants of Î±2,-Adrenergic Receptor Regulation. Advances in Pharmacology, 1997, 42, 438-442.	1.2	5
173	Î±2A-Adrenergic Receptor Stimulated Calcium Release Is Transduced by Gi-Associated GÎ²Î³-Mediated Activation of Phospholipase Câ€. Biochemistry, 1997, 36, 6415-6423.	1.2	80
174	Role of the Amino Terminus of the Third Intracellular Loop in Agonist-Promoted Downregulation of the Î±2A-Adrenergic Receptorâ€. Biochemistry, 1997, 36, 8858-8863.	1.2	22
175	Effects of Thyroid Hormone on Cardiac Î²-Adrenergic Responsiveness in Conscious Baboons. Circulation, 1997, 96, 592-598.	1.6	89
176	Chimeric Mutagenesis of Putative G-protein Coupling Domains of the Î±2A-Adrenergic Receptor. Journal of Biological Chemistry, 1996, 271, 12826-12832.	1.6	80
177	G Protein-coupled Receptor Kinase Specificity for Phosphorylation and Desensitization of Î±2-Adrenergic Receptor Subtypes. Journal of Biological Chemistry, 1996, 271, 18082-18087.	1.6	75
178	Sustained Activation of a G Protein-coupled Receptor via â€œAnchoredâ€•Agonist Binding. Journal of Biological Chemistry, 1996, 271, 24029-24035.	1.6	135
179	Phosphorylation and Desensitization of the Human Î²1-Adrenergic Receptor. Journal of Biological Chemistry, 1995, 270, 17953-17961.	1.6	284
180	Four Consecutive Serines in the Third Intracellular Loop Are the Sites for Î²-Adrenergic Receptor Kinase-mediated Phosphorylation and Desensitization of the Î±2A-Adrenergic Receptor. Journal of Biological Chemistry, 1995, 270, 4681-4688.	1.6	115

#	Article	IF	Citations
181	Identification of a Gs Coupling Domain in the Amino Terminus of the Third Intracellular Loop of the Î±2A-Adrenergic Receptor. Journal of Biological Chemistry, 1995, 270, 24753-24760.	1.6	96
182	An Acidic Motif within the Third Intracellular Loop of the .alpha.2C2 Adrenergic Receptor Is Required for Agonist-Promoted Phosphorylation and Desensitization. Biochemistry, 1995, 34, 11946-11953.	1.2	48
183	Amino-Terminal Polymorphisms of the Human .beta.2-Adrenergic Receptor Impart Distinct Agonist-Promoted Regulatory Properties. Biochemistry, 1994, 33, 9414-9419.	1.2	745
184	Mutations in the Gene Encoding for the Î²₂-adrenergic Receptor in Normal and Asthmatic Subjects. American Journal of Respiratory Cell and Molecular Biology, 1993, 8, 334-339.	1.4	622
185	Desensitization of the Î²-adrenergic recepton: Distinct molecular determinants of phosphorylation by specific kinases. Pharmacological Research, 1991, 24, 29-41.	3.1	23
186	system of the human macrophage U937 cell line. European Journal of Pharmacology, 1989, 163, 171-174.	1.7	19